

# FDA approves continuous glucose monitoring system

29 June 2018



and the procedure used to implant it were also assessed. The proportion of individuals who experienced a serious adverse event was less than 1 percent. Approval of the Eversense CGM System was granted to Senseonics Inc.

"The FDA is committed to advancing novel products that leverage digital technology to improve patient care," FDA Commissioner Scott Gottlieb, M.D., said in a statement. "These technologies allow patients to gain better control over their health."

**More information:** [More Information](#)

Copyright © 2018 [HealthDay](#). All rights reserved.

(HealthDay)—The Eversense Continuous Glucose Monitoring (CGM) system, which has a fully implantable sensor to detect glucose, has been approved by the U.S. Food and Drug Administration for use in people age 18 years and older with diabetes.

The Eversense CGM uses a small sensor, which is implanted just under the skin by a qualified health care provider. The sensor regularly measures [glucose levels](#) in adults with diabetes for up to 90 days after implantation. The sensor works with a novel light-based [technology](#) to measure [glucose](#) levels and alerts users via a message sent to a mobile app in cases of hyper- or hypoglycemia.

In order to review the device's effectiveness, the FDA assessed clinical study data from 125 individuals (aged 18 years and older) and compared readings obtained by the Eversense CGM with those obtained by a laboratory-based glucose analyzer. During the clinical studies, the safety of the CGM system's implantable sensor

APA citation: FDA approves continuous glucose monitoring system (2018, June 29) retrieved 26 January 2021 from <https://medicalxpress.com/news/2018-06-fda-glucose.html>

*This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.*